NASDAQ: BNTC
Benitec Biopharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for BNTC

Based on 4 analysts offering 12 month price targets for Benitec Biopharma Inc

Min Forecast
$17.00+25.09%
Avg Forecast
$23.75+74.76%
Max Forecast
$30.00+120.75%

Should I buy or sell BNTC stock?

Based on 4 analysts offering ratings for Benitec Biopharma Inc.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BNTC's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BNTC as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BNTC stock forecasts and price targets.

BNTC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-03-24
lockedlocked$00.00+00.00%2024-12-13
lockedlocked$00.00+00.00%2024-12-03

1 of 1

Forecast return on equity

Is BNTC forecast to generate an efficient return?

Company
-58.67%
Industry
142.9%
Market
80.27%
BNTC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BNTC forecast to generate an efficient return on assets?

Company
-56.35%
Industry
35.65%
BNTC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BNTC earnings per share forecast

What is BNTC's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.52
Avg 2 year Forecast
-$2.28
Avg 3 year Forecast
-$2.61

BNTC revenue forecast

What is BNTC's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$15.6M
Avg 2 year Forecast
$75.6M
Avg 3 year Forecast
$246.6M

BNTC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BNTC$13.59$23.75+74.76%Strong Buy
ABEO$6.56$17.00+159.15%Buy
TPST$7.11$9.33+31.27%Buy
RNAC$12.00$41.00+241.67%Strong Buy
SEPN$6.96$33.00+374.14%Strong Buy

Benitec Biopharma Stock Forecast FAQ

Is Benitec Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BNTC) stock is to Strong Buy BNTC stock.

Out of 4 analysts, 1 (25%) are recommending BNTC as a Strong Buy, 3 (75%) are recommending BNTC as a Buy, 0 (0%) are recommending BNTC as a Hold, 0 (0%) are recommending BNTC as a Sell, and 0 (0%) are recommending BNTC as a Strong Sell.

If you're new to stock investing, here's how to buy Benitec Biopharma stock.

What is BNTC's earnings growth forecast for 2025-2027?

(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Benitec Biopharma's earnings in 2025 is -$22,034,000.On average, 4 Wall Street analysts forecast BNTC's earnings for 2025 to be -$35,704,871, with the lowest BNTC earnings forecast at -$39,398,478, and the highest BNTC earnings forecast at -$28,610,800. On average, 3 Wall Street analysts forecast BNTC's earnings for 2026 to be -$53,546,753, with the lowest BNTC earnings forecast at -$87,239,487, and the highest BNTC earnings forecast at -$27,907,255.

In 2027, BNTC is forecast to generate -$61,091,092 in earnings, with the lowest earnings forecast at -$75,513,750 and the highest earnings forecast at -$46,668,435.

What is BNTC's revenue growth forecast for 2028-2030?

(NASDAQ: BNTC) Benitec Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Benitec Biopharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast BNTC's revenue for 2028 to be $364,904,951, with the lowest BNTC revenue forecast at $110,690,962, and the highest BNTC revenue forecast at $619,118,940. On average, 2 Wall Street analysts forecast BNTC's revenue for 2029 to be $1,773,752,312, with the lowest BNTC revenue forecast at $1,436,168,329, and the highest BNTC revenue forecast at $2,111,336,294.

In 2030, BNTC is forecast to generate $5,782,664,706 in revenue, with the lowest revenue forecast at $2,773,136,919 and the highest revenue forecast at $8,792,192,492.

What is BNTC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BNTC) forecast ROA is -56.35%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is BNTC's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BNTC price target, the average BNTC price target is $23.75, with the highest BNTC stock price forecast at $30.00 and the lowest BNTC stock price forecast at $17.00.

On average, Wall Street analysts predict that Benitec Biopharma's share price could reach $23.75 by Apr 10, 2026. The average Benitec Biopharma stock price prediction forecasts a potential upside of 74.76% from the current BNTC share price of $13.59.

What is BNTC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BNTC) Benitec Biopharma's current Earnings Per Share (EPS) is -$0.01. On average, analysts forecast that BNTC's EPS will be -$1.52 for 2025, with the lowest EPS forecast at -$1.68, and the highest EPS forecast at -$1.22. On average, analysts forecast that BNTC's EPS will be -$2.28 for 2026, with the lowest EPS forecast at -$3.72, and the highest EPS forecast at -$1.19. In 2027, BNTC's EPS is forecast to hit -$2.61 (min: -$3.22, max: -$1.99).

What is BNTC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BNTC) forecast ROE is -58.67%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.